ACAP3

Across TCGA pan-cancer cohorts, ACAP3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACAP3 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACAP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACAP3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where ACAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	1.000	0.475	.006	15	view →
HNSC	OS	Quartile	All	1.000	0.721	.004	13	view →
LUAD	OS	Quartile	All	0.540	0.903	.006	11	view →
LSCC	DFS	Quartile	III,IV	0.337	0.875	.008	6	view →
PDAC	DFS	Quartile	III,IV	0.843	0.206	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACAP3–CCRCC (DFS)

Open the CCRCC breakdown →